EPS profiles: the atypical antipsychotics are not all the same.
作者： PETER J. WEIDEN
DOI: 10.1097/00131746-200701000-00003
关键词:
摘要: … of EPS. This review discusses differences among the SGAs in EPS liability, relationships between dosing and type of EPS, and situations in which differences in EPS liability among the …
lww.com
sci-hub.se 参考文章(62)
Charles M Beasley Jr, Gary Tollefson, Pierre Tran, Winston Satterlee, Todd Sanger, Susan Hamilton, Olanzapine HGAD Study Group, Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial Neuropsychopharmacology. ,vol. 14, pp. 111- 123 ,(1996) , 10.1016/0893-133X(95)00069-P
Ralph Aquila, Janet M. Standard, Laura Dalheim, Peter J. Weiden, Switching antipsychotic medications. The Journal of Clinical Psychiatry. ,vol. 58, pp. 63- 72 ,(1997)
D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. American Journal of Psychiatry. ,vol. 152, pp. 1444- 1449 ,(1995) , 10.1176/AJP.152.10.1444
Shitij Kapur, David Mamo, Half a century of antipsychotics and still a central role for dopamine D2 receptors Progress in Neuro-Psychopharmacology and Biological Psychiatry. ,vol. 27, pp. 1081- 1090 ,(2003) , 10.1016/J.PNPBP.2003.09.004
Pierre V Tran, Gary D Tollefson, Todd M Sanger, Yili Lu, Paul H Berg, Charles M Beasley, None, Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. British Journal of Psychiatry. ,vol. 174, pp. 15- 22 ,(1999) , 10.1192/BJP.174.1.15
GERARD ADDONIZIO, Rapid induction of extrapyramidal side effects with combined use of lithium and neuroleptics. Journal of Clinical Psychopharmacology. ,vol. 5, pp. 296- 298 ,(1985) , 10.1097/00004714-198510000-00008
Ross J Baldessarini, Bruce M Cohen, Martin H Teicher, Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses Archives of General Psychiatry. ,vol. 45, pp. 79- 91 ,(1988) , 10.1001/ARCHPSYC.1988.01800250095013
Pierre V. Tran, Mary Anne Dellva, Gary D. Tollefson, Charles M. Beasley, Janet H. Potvin, Gerilyn M. Kiesler, Extrapyramidal Symptoms and Tolerability of Olanzapine Versus Haloperidol in the Acute Treatment of Schizophrenia The Journal of Clinical Psychiatry. ,vol. 58, pp. 205- 211 ,(1997) , 10.4088/JCP.V58N0505
Ira R. Katz, Dilip V. Jeste, Jacobo E. Mintzer, Christopher Clyde, Judy Napolitano, Martin Brecher, , Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. The Journal of Clinical Psychiatry. ,vol. 60, pp. 107- 115 ,(1999) , 10.4088/JCP.V60N0207
Peter J. Weiden, David G. Daniel, George Simpson, Steven J. Romano, Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. Journal of Clinical Psychopharmacology. ,vol. 23, pp. 595- 600 ,(2003) , 10.1097/01.JCP.0000095347.32154.08